Beclometasone

Beclometasone (Beclomethasone) is a prototype glucocorticoid receptor agonist. IC50 & Target: Glucocorticoid Receptor^[1] In Vitro: An inhibition of the normal physiological neutrophil migration and of neutrophil chemotaxis directed by wounding-induced inflammation is detected at 4 h after administration of 25 μM Beclomethasone. Tumour cell invasion and micrometastasis is also reduced in embryos incubated in 25 μM Beclomethasone 4 h before implantation. In addition, the lysyl oxidase inhibitor β-aminoproprionitrile (βAPN) largely reduces fibrillar collagen and enhances the CHT-TF transmigration of neutrophils, leading to a significant increase of tumour cell invasion and subsequent formation of micrometastases. Notably, βAPN inhibits neutrophil chemotaxis induced by inflammation, indicating that the increase of tumour cell invasion in βAPN-treated embryos is correlated with enhanced non-pathological neutrophil migration, but not with inflammation^[1].